- Home
- SEVN vs NYXH Comparison
SEVN vs NYXH Comparison
Compare SEVN & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEVN
- NYXH
- Stock Information
- Founded
- SEVN 1986
- NYXH 2009
- Country
- SEVN United States
- NYXH Belgium
- Employees
- SEVN N/A
- NYXH N/A
- Industry
- SEVN Real Estate Investment Trusts
- NYXH Medical/Dental Instruments
- Sector
- SEVN Real Estate
- NYXH Health Care
- Exchange
- SEVN Nasdaq
- NYXH Nasdaq
- Market Cap
- SEVN 161.7M
- NYXH 179.1M
- IPO Year
- SEVN N/A
- NYXH 2021
- Fundamental
- Price
- SEVN $10.97
- NYXH $4.66
- Analyst Decision
- SEVN Strong Buy
- NYXH Strong Buy
- Analyst Count
- SEVN 2
- NYXH 3
- Target Price
- SEVN $13.50
- NYXH $15.00
- AVG Volume (30 Days)
- SEVN 38.1K
- NYXH 63.1K
- Earning Date
- SEVN 10-27-2025
- NYXH 11-05-2025
- Dividend Yield
- SEVN 10.06%
- NYXH N/A
- EPS Growth
- SEVN N/A
- NYXH N/A
- EPS
- SEVN 1.04
- NYXH N/A
- Revenue
- SEVN $29,272,000.00
- NYXH $5,793,306.00
- Revenue This Year
- SEVN N/A
- NYXH $118.20
- Revenue Next Year
- SEVN N/A
- NYXH $278.04
- P/E Ratio
- SEVN $10.68
- NYXH N/A
- Revenue Growth
- SEVN N/A
- NYXH 2.94
- 52 Week Low
- SEVN $10.01
- NYXH $4.56
- 52 Week High
- SEVN $14.66
- NYXH $11.87
- Technical
- Relative Strength Index (RSI)
- SEVN 54.65
- NYXH 22.22
- Support Level
- SEVN $10.75
- NYXH $4.56
- Resistance Level
- SEVN $11.04
- NYXH $6.09
- Average True Range (ATR)
- SEVN 0.18
- NYXH 0.27
- MACD
- SEVN 0.02
- NYXH -0.10
- Stochastic Oscillator
- SEVN 67.86
- NYXH 5.24
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.